Bruker Corporation (NASDAQ:BRKR) was upgraded by research analysts at J P Morgan Chase & Co from an “underweight” rating to a “neutral” rating in a note issued to investors on Friday. The firm currently has a $28.00 target price on the medical research company’s stock. J P Morgan Chase & Co’s target price suggests a potential downside of 16.02% from the stock’s current price.
Other research analysts also recently issued research reports about the company. Wells Fargo & Company downgraded Bruker Corporation from a “market perform” rating to an “underperform” rating in a research note on Wednesday, July 12th. Zacks Investment Research upgraded Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Thursday, July 6th. BidaskClub downgraded Bruker Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Barclays PLC restated an “equal weight” rating and issued a $30.00 target price (up previously from $26.00) on shares of Bruker Corporation in a research note on Monday, July 17th. Finally, Cowen and Company restated a “hold” rating and issued a $29.00 target price on shares of Bruker Corporation in a research note on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $28.58.
Shares of Bruker Corporation (NASDAQ BRKR) traded up $2.04 during midday trading on Friday, reaching $33.34. The company’s stock had a trading volume of 2,025,191 shares, compared to its average volume of 444,070. The company has a quick ratio of 1.61, a current ratio of 2.63 and a debt-to-equity ratio of 0.56. Bruker Corporation has a 1 year low of $21.03 and a 1 year high of $35.16. The stock has a market capitalization of $5,279.46, a P/E ratio of 28.50, a P/E/G ratio of 3.44 and a beta of 1.05.
Bruker Corporation (NASDAQ:BRKR) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. Bruker Corporation had a return on equity of 25.93% and a net margin of 8.85%. The firm had revenue of $435.60 million for the quarter, compared to the consensus estimate of $415.45 million. During the same quarter in the previous year, the company posted $0.32 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. equities research analysts forecast that Bruker Corporation will post 1.17 EPS for the current fiscal year.
In related news, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $29.97, for a total transaction of $631,198.17. Following the completion of the transaction, the vice president now owns 60,524 shares of the company’s stock, valued at approximately $1,813,904.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Frank H. Laukien acquired 2,335 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were acquired at an average cost of $27.39 per share, with a total value of $63,955.65. Following the transaction, the chief executive officer now directly owns 37,791,386 shares in the company, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. 35.20% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of BRKR. UBS Asset Management Americas Inc. lifted its position in shares of Bruker Corporation by 18.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 73,058 shares of the medical research company’s stock worth $1,704,000 after purchasing an additional 11,324 shares during the last quarter. Teachers Advisors LLC lifted its position in shares of Bruker Corporation by 20.5% during the 1st quarter. Teachers Advisors LLC now owns 148,229 shares of the medical research company’s stock worth $3,458,000 after purchasing an additional 25,225 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Bruker Corporation by 189.8% during the 1st quarter. Legal & General Group Plc now owns 34,905 shares of the medical research company’s stock worth $815,000 after purchasing an additional 22,861 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Bruker Corporation by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 9,832,452 shares of the medical research company’s stock worth $229,391,000 after purchasing an additional 277,111 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Bruker Corporation by 7.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 944,553 shares of the medical research company’s stock worth $22,034,000 after purchasing an additional 66,344 shares during the last quarter. 65.74% of the stock is owned by institutional investors and hedge funds.
Bruker Corporation Company Profile
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
What are top analysts saying about Bruker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bruker Corporation and related companies.